Goldman Sachs Initiates Coverage On GSK with Neutral Rating, Announces Price Target of $47
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs has initiated coverage on GSK with a Neutral rating and set a price target of $47.
May 30, 2024 | 10:44 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs has initiated coverage on GSK with a Neutral rating and set a price target of $47.
The Neutral rating suggests that Goldman Sachs does not expect significant short-term movement in GSK's stock price. The price target of $47 provides a benchmark for investors but does not indicate a strong buy or sell signal.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100